Braveheart Bio, Inc. - 10-Q Filing

Braveheart Bio, Inc. reports Q3 2026 financial results with 89.87 million common shares outstanding as of November 6, 2026.

SEC EDGAR ·

Tickers: $BRVE

Read the full article at SEC EDGAR

More Regulatory news